Atherotech Names Ted Fendley Vice President of Operations; Laboratory Industry Veteran to Concentrate on Meeting Growing Demand for the VAP Cholesterol Test.

Business Editors/Health/Medical Writers

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Sept. 9, 2003

Atherotech, Inc., a leading cardiodiagnostic company and developer of the VAP(TM) (Vertical Auto Profile) Cholesterol Test, today announced the appointment of Ted W. Fendley, Ph.D., as vice president of operations. Fendley will focus on ensuring the operating efficiency and high quality of the company's state-of-the-art laboratory facilities designed to process the VAP Cholesterol Test, as well as expanding capacity to meet growing demand.

Fendley's professional experience includes more than 30 years in medical laboratory operations at leading national and regional labs, where he successfully developed and implemented a number of programs to increase efficiency, reduce costs, increase revenue, and improve quality. Most recently, he served for more than 15 years as associate vice president at Laboratory Corporation of America. He also has held senior management positions at Medical Diagnostic Services, Medical Laboratory Associates, and Pathology and Cytology Laboratory.

According to Roseanne Varner, Atherotech's president and chief executive officer, the company has achieved substantial growth in recent years as physicians across the country continue to recognize the importance of the VAP Cholesterol Test in the early diagnosis and treatment of heart disease. "We are delighted to welcome Ted as a key member of the Atherotech senior management team," Varner said. "His wealth of laboratory management experience will serve as an invaluable resource, allowing us to meet the ever-increasing demand for the VAP Cholesterol Test and better serve our physician and clinical laboratory customers."

"I am pleased to join Atherotech at this exciting time and share the company's commitment to delivering the highest level of quality and customer service," Fendley said. "Atherotech is recognized for providing fast, accurate, and affordable test results and has consistently upgraded its laboratory operations to include the latest in diagnostic technology. I look forward to working with the company to establish the VAP Cholesterol Test as the new standard of care in cholesterol risk assessment."

The VAP Cholesterol Test provides direct, detailed measurements of cholesterol subclasses that play important roles in the development of heart disease but are not measured by routine lipid panels. The VAP Test complies with updated National Cholesterol Education Program guidelines, which highlight emerging risk factors and secondary targets of therapy for heart disease. It requires a small blood sample, and results are returned to physicians by fax or e-mail within 72 hours or can be accessed online. The VAP Test is reimbursed by most insurance carriers, and the company accepts assignment from Medicare and Blue Cross/Blue Shield PMD.

Atherotech, a leading cardiodiagnostic company and specialty reference laboratory based in Birmingham, is dedicated to improving the early diagnosis and treatment of heart disease and other cardiovascular diseases that kill nearly a million Americans each year. For more information, visit the company's Web site at www.thevaptest.com.

Note to editors: A detailed bio and photo of Ted Fendley are available upon request.